Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has issued an update.
CSL Limited has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that it had repurchased a cumulative total of 3,971,077 shares prior to the latest trading day and bought back an additional 59,751 shares on the previous day.
The update, dated 5 March 2026, forms part of CSL’s daily buy-back disclosures that commenced with an initial notification in August 2025. This continued execution of on-market repurchases signals an active capital management strategy that can support earnings per share accretion and may be viewed as an indication of management’s confidence in the company’s valuation and long-term outlook.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$164.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a publicly listed company on the ASX that has issued ordinary fully paid shares under the security code CSL. The company operates in the healthcare and biotechnology sector, focusing on the development and commercialisation of biopharmaceutical products and related medical therapies for global markets.
Average Trading Volume: 1,136,457
Technical Sentiment Signal: Sell
Current Market Cap: A$70.46B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.